FMZ Fludarabine, Mitoxantrone, Zevalin regimen a phase II study as front-line treatment in indolent non-follicular non-Hodgkins lymphoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002302-30-IT

Enrollment

Registered

2006-02-16

Start date

2004-07-20

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Confirmed histologic diagnosis according to the REAL classification of B-cell indolent lymphoma including small lymphocytic, immunocytoma, and marginal zone lymphoma MedDRA version: 6.1 Level: HLT Classification code 10003900

Interventions

Trade Name: zevalin Pharmaceutical Form: Solution for injection Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.2-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026